Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;5(10):2781-2791.
doi: 10.1002/cam4.877. Epub 2016 Sep 20.

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score-matched analysis

Xiuwen Geng  1   2 , Hao Liu  1 , Tian Lin  1 , Yanfeng Hu  1 , Hao Chen  1 , Liying Zhao  1 , Tingyu Mou  1 , Xiaolong Qi  3 , Jiang Yu  4 , Guoxin Li  5
Affiliations

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score-matched analysis

Xiuwen Geng et al. Cancer Med. 2016 Oct.

Abstract

Peritoneal carcinomatosis (PC) is the most frequent pattern of metastasis in stage IV gastric cancer (GC). The study aims to investigate the efficacy of gastrectomy in GC with PC. Clinicopathological data of 518 stage IV GC patients were retrospectively collected in Nanfang Hospital. Among all cases, 312 GC patients with PC (without other site of metastasis) were eligible. Univariate and multivariate analyses were performed to identify the independent prognostic factors. Propensity score matching analysis was performed to balance the characteristics and treatment-related factors. There was a significantly improved overall survival in gastrectomy group (148 patients) compared with nonresection group (164 patients) (P < 0.001). The 1-year and 2-year survival rates were 49.8% and 21.5% in gastrectomy group, whereas 28.8% and 9.7% in nonresection group, respectively. Further analysis showed that gastrectomy had also improved survival in P1 (P = 0.017) and P2 stage patients (P < 0.001), but not P3 stage (P = 0.495). The modality of gastrectomy plus chemotherapy plus hyperthermic intraperitoneal chemotherapy (HIPEC) showed an optimum survival. In addition, P3 disease, nongastrectomy, nonchemotherapy, non-HIPEC, and age ≥ 60 years were independently associated with poor survival. The gastrectomy plus chemotherapy plus HIPEC modality showed a significant survival benefit for gastric adenocarcinoma patients, particularly in those with P1 and P2 diseases.

Keywords: Chemotherapy; gastrectomy; gastric cancer; peritoneal carcinomatosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Selection and grouping of stage IV gastric adenocarcinoma patients with peritoneal carcinomatosis.
Figure 2
Figure 2
Overall survival and survivals of different treatment subgroups of stage IV gastric adenocarcinoma patients with peritoneal carcinomatosis.
Figure 3
Figure 3
Overall survival and P stage subgroup survivals of stage IV gastric adenocarcinoma patients with peritoneal carcinomatosis.
See this image and copyright information in PMC

References

    1. Jemal, A. , Siegel R., Xu J., and Ward E.. 2010. Cancer statistics, 2010. CA Cancer J. Clin. 60:277–300. - PubMed
    1. Chen, S. , Li Y. F., Feng X. Y., Zhou Z. W., Yuan X. H., and Chen Y. B.. 2012. Significance of palliative gastrectomy for late‐stage gastric cancer patients. J. Surg. Oncol. 106:862–871. - PubMed
    1. Chen, W. , Zheng R., Baade P. D., Zhang S., Zeng H., Bray F., et al. 2016. Cancer statistics in China, 2015. CA Cancer J. Clin. 66:115–132. - PubMed
    1. Yonemura, Y. , Endou Y., Shinbo M., Sasaki T., Hirano M., Mizumoto A., et al. 2009. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: selection for cytoreductive surgery. J. Surg. Oncol. 100:311–316. - PubMed
    1. Bando, E. , Yonemura Y., Takeshita Y., Taniguchi K., Yasui T., Yoshimitsu Y., et al. 1999. Intraoperative lavage for cytological examination in 1297 patients with gastric carcinoma. Am. J. Surg. 178:256–262. - PubMed